(Q37785214)

23 August 2017

title

Drug development for cancer chemoprevention: focus on molecular targets (English)

1 reference

23 August 2017

Drug Development for Cancer Chemoprevention: Focus on Molecular Targets (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

2

Powel H. Brown

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816505

6 July 2024

author name string

Karen A. Johnson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816505

6 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20816505

6 July 2024

publication date

1 August 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0093775410000771?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

https://api.elsevier.com/content/article/PII:S0093775410000771?httpAccept=text/plain

6 July 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

1 reference

23 August 2017

volume

37

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

345-358

1 reference

David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Phase II and III clinical trials of toremifene for metastatic breast cancer

6 July 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

6 July 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer

6 July 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Exemestane, a new steroidal aromatase inhibitor of clinical relevance

6 July 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer

6 July 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

Lapatinib

9

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Flutamide: an antiandrogen for advanced prostate cancer

6 July 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

6 July 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

Cetuximab

12

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer

6 July 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

Gefitinib

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

Sorafenib and sunitinib.

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

Everolimus

17

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Steroid hormone receptors in breast cancer management

6 July 2024

18

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Tamoxifen and contralateral breast cancer

6 July 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

6 July 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer

6 July 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

6 July 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

6 July 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

6 July 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

6 July 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

6 July 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The pharmacology of letrozole

6 July 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast

6 July 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity

6 July 2024

30

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Update on the use of aromatase inhibitors in breast cancer

6 July 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Intratumoral estrogen disposition in breast cancer

6 July 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

6 July 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment

6 July 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

6 July 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

6 July 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole

6 July 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial

6 July 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The endocrine prevention of breast cancer

6 July 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes

6 July 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.

6 July 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis

6 July 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Chemoprevention of prostate cancer

6 July 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

5 alpha-reductase inhibitors: what's new?

6 July 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The influence of finasteride on the development of prostate cancer

6 July 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Effect of dutasteride on the risk of prostate cancer

6 July 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force

6 July 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

6 July 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

6 July 2024

49

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force

6 July 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Low-dose aspirin and incidence of colorectal tumors in a randomized trial

6 July 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

6 July 2024

52

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Point/Counterpoint: Aspirin should not be promoted for colon cancer prevention: counterpoint

6 July 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Celecoxib for the prevention of sporadic colorectal adenomas

6 July 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Celecoxib for the prevention of colorectal adenomatous polyps

6 July 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

6 July 2024

56

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

6 July 2024

57

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial

6 July 2024

58

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention

6 July 2024

59

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells

6 July 2024

60

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The management of intraductal papillary mucinous neoplasms of the pancreas

6 July 2024

61

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Molecular targets for cancer chemoprevention

6 July 2024

62

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment

6 July 2024

63

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry

6 July 2024

64

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Molecular predictive factors for progression of high-grade preinvasive bronchial lesions

6 July 2024

65

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis

6 July 2024

66

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma

6 July 2024

67

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia

6 July 2024

69

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

BRCA1 regulates human mammary stem/progenitor cell fate

6 July 2024

70

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Targeting breast stem cells with the cancer preventive compounds curcumin and piperine

6 July 2024

71

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Serous carcinogenesis in the fallopian tube: a descriptive classification.

6 July 2024

72

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

6 July 2024

73

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Ten genes for inherited breast cancer.

6 July 2024

74

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

6 July 2024

75

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

6 July 2024

76

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

6 July 2024

77

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

6 July 2024

78

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women

6 July 2024

79

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Application of comparative functional genomics to identify best-fit mouse models to study human cancer

6 July 2024

81

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Significance analysis of microarrays applied to the ionizing radiation response

6 July 2024

82

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

6 July 2024

83

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

6 July 2024

84

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer

6 July 2024

85

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways

6 July 2024

86

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

FDA drug approval summary: erlotinib (Tarceva) tablets

6 July 2024

87

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis

6 July 2024

88

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells.

6 July 2024

89

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells

6 July 2024

90

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins

6 July 2024

91

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Green tea catechins in chemoprevention of cancer: a molecular docking investigation into their interaction with glutathione S-transferase (GST P1-1)

6 July 2024

92

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies

6 July 2024

93

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids

6 July 2024

94

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

DNA and RNA as new binding targets of green tea catechins.

6 July 2024

95

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Tea polyphenols, their biological effects and potential molecular targets

6 July 2024

96

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Green tea (Camellia sinensis) for the prevention of cancer

6 July 2024

97

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta

6 July 2024

98

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols.

6 July 2024

99

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

MEK4 function, genistein treatment, and invasion of human prostate cancer cells

6 July 2024

100

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Multi-targeted therapy of cancer by genistein

6 July 2024

101

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Molecular biology of the Ah receptor and its role in carcinogenesis

6 July 2024

102

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast.

6 July 2024

103

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta

6 July 2024

104

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Crystal structure of quinone reductase 2 in complex with resveratrol

6 July 2024

105

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators.

6 July 2024

106

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Oxidation of dietary polyphenolics by hydroperoxidase activity of lipoxygenase

6 July 2024

107

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan

6 July 2024

108

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Clusterin mediates TRAIL resistance in prostate tumor cells

6 July 2024

109

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Target identification using drug affinity responsive target stability (DARTS)

6 July 2024

110

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Therapeutic potential of resveratrol: the in vivo evidence

6 July 2024

111

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms

6 July 2024

112

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.05.012

6 July 2024

Identifiers

1 reference

23 August 2017

1 reference